WBC17_NiteshDaveBlog

What happens to Biosimilars being developed under 505b (2)?

In Americas, Antibodies by Karina KusovaLeave a Comment

Nitesh Dave of Biocon joined us for World Biosimilar Congress USA 2016 to discuss what happens to biosimilars being developed under 505b (2).

Download this presentation to understand more about:

  • Key features of 505b (2)
  • Key features of 351k (1, 2)
  • Products approved under 505b (2)
  • Path ahead for products under development

and more!

Get your copy here!

If you’re interested in learning more about biosimilars being developed, join us for World Biosimilar Congress USA 2017 , held May 23-24 in San Diego, CA . This event is co-located with Americas Antibody Congress and Cell Culture World Congress USA.

Biosimilars_LearnMoreNow

Leave a Comment

Current ye@r *